267 related articles for article (PubMed ID: 25224012)
1. NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.
Reghellin V; Donnici L; Fenu S; Berno V; Calabrese V; Pagani M; Abrignani S; Peri F; De Francesco R; Neddermann P
Antimicrob Agents Chemother; 2014 Dec; 58(12):7128-40. PubMed ID: 25224012
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity.
Bianco A; Reghellin V; Donnici L; Fenu S; Alvarez R; Baruffa C; Peri F; Pagani M; Abrignani S; Neddermann P; De Francesco R
PLoS Pathog; 2012; 8(3):e1002576. PubMed ID: 22412376
[TBL] [Abstract][Full Text] [Related]
3. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C Virus Subverts Human Choline Kinase-α To Bridge Phosphatidylinositol-4-Kinase IIIα (PI4KIIIα) and NS5A and Upregulates PI4KIIIα Activation, Thereby Promoting the Translocation of the Ternary Complex to the Endoplasmic Reticulum for Viral Replication.
Wong MT; Chen SS
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566381
[TBL] [Abstract][Full Text] [Related]
5. Mapping of functional domains of the lipid kinase phosphatidylinositol 4-kinase type III alpha involved in enzymatic activity and hepatitis C virus replication.
Harak C; Radujkovic D; Taveneau C; Reiss S; Klein R; Bressanelli S; Lohmann V
J Virol; 2014 Sep; 88(17):9909-26. PubMed ID: 24920820
[TBL] [Abstract][Full Text] [Related]
6. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment.
Reiss S; Rebhan I; Backes P; Romero-Brey I; Erfle H; Matula P; Kaderali L; Poenisch M; Blankenburg H; Hiet MS; Longerich T; Diehl S; Ramirez F; Balla T; Rohr K; Kaul A; Bühler S; Pepperkok R; Lengauer T; Albrecht M; Eils R; Schirmacher P; Lohmann V; Bartenschlager R
Cell Host Microbe; 2011 Jan; 9(1):32-45. PubMed ID: 21238945
[TBL] [Abstract][Full Text] [Related]
7. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
[TBL] [Abstract][Full Text] [Related]
8. Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents.
Leivers AL; Tallant M; Shotwell JB; Dickerson S; Leivers MR; McDonald OB; Gobel J; Creech KL; Strum SL; Mathis A; Rogers S; Moore CB; Botyanszki J
J Med Chem; 2014 Mar; 57(5):2091-106. PubMed ID: 23944386
[TBL] [Abstract][Full Text] [Related]
9. The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A.
Reiss S; Harak C; Romero-Brey I; Radujkovic D; Klein R; Ruggieri A; Rebhan I; Bartenschlager R; Lohmann V
PLoS Pathog; 2013 May; 9(5):e1003359. PubMed ID: 23675303
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation.
Lim YS; Hwang SB
J Biol Chem; 2011 Apr; 286(13):11290-8. PubMed ID: 21297162
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication.
Berger KL; Kelly SM; Jordan TX; Tartell MA; Randall G
J Virol; 2011 Sep; 85(17):8870-83. PubMed ID: 21697487
[TBL] [Abstract][Full Text] [Related]
12. Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.
Chatterji U; Bobardt M; Tai A; Wood M; Gallay PA
Antimicrob Agents Chemother; 2015 May; 59(5):2496-507. PubMed ID: 25666154
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.
Vaillancourt FH; Brault M; Pilote L; Uyttersprot N; Gaillard ET; Stoltz JH; Knight BL; Pantages L; McFarland M; Breitfelder S; Chiu TT; Mahrouche L; Faucher AM; Cartier M; Cordingley MG; Bethell RC; Jiang H; White PW; Kukolj G
J Virol; 2012 Nov; 86(21):11595-607. PubMed ID: 22896614
[TBL] [Abstract][Full Text] [Related]
14. Phosphoinositides in the hepatitis C virus life cycle.
Bishé B; Syed G; Siddiqui A
Viruses; 2012 Oct; 4(10):2340-58. PubMed ID: 23202467
[TBL] [Abstract][Full Text] [Related]
15. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.
Targett-Adams P; Graham EJ; Middleton J; Palmer A; Shaw SM; Lavender H; Brain P; Tran TD; Jones LH; Wakenhut F; Stammen B; Pryde D; Pickford C; Westby M
J Virol; 2011 Jul; 85(13):6353-68. PubMed ID: 21507963
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus NS5A competes with PI4KB for binding to ACBD3 in a genotype-dependent manner.
Hong Z; Yang X; Yang G; Zhang L
Antiviral Res; 2014 Jul; 107():50-5. PubMed ID: 24792752
[TBL] [Abstract][Full Text] [Related]
17. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein.
Lee C; Ma H; Hang JQ; Leveque V; Sklan EH; Elazar M; Klumpp K; Glenn JS
Virology; 2011 May; 414(1):10-8. PubMed ID: 21513964
[TBL] [Abstract][Full Text] [Related]
18. PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases.
Delang L; Harak C; Benkheil M; Khan H; Leyssen P; Andrews M; Lohmann V; Neyts J
J Antimicrob Chemother; 2018 Dec; 73(12):3375-3384. PubMed ID: 30219827
[TBL] [Abstract][Full Text] [Related]
19. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.
McGivern DR; Masaki T; Williford S; Ingravallo P; Feng Z; Lahser F; Asante-Appiah E; Neddermann P; De Francesco R; Howe AY; Lemon SM
Gastroenterology; 2014 Aug; 147(2):453-62.e7. PubMed ID: 24768676
[TBL] [Abstract][Full Text] [Related]
20. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.
Qiu D; Lemm JA; O'Boyle DR; Sun JH; Nower PT; Nguyen V; Hamann LG; Snyder LB; Deon DH; Ruediger E; Meanwell NA; Belema M; Gao M; Fridell RA
J Gen Virol; 2011 Nov; 92(Pt 11):2502-2511. PubMed ID: 21795470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
